Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea

Overview

South Korea has the highest incidence of gastric cancer worldwide and Helicobacter pylori infection is still prevalent. Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government. However, studies of antibiotic resistance has shown that regional resistance pattern to antibiotics such as clarithromycin, metronidazole, or quinolone. Recent study in Korea has shown that modified-quadruple therapy has comparable eradication rate to concomitant therapy. However, there has been no comparable study of modified-quadruple therapy with bismuth-containing quadruple therapy. The aim of this study is to compare the eradication rate of modified-quadruple therapy and bismuth-containing quadruple therapy with presenting phenotypic and genotypic antibiotic resistance profile.

Full Title of Study: “Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea; Open-label, Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 6, 2019

Detailed Description

South Korea has the highest incidence of gastric cancer worldwide and Helicobacter pylori infection is still prevalent. Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government. However, studies of antibiotic resistance has shown that regional resistance pattern to antibiotics such as clarithromycin, metronidazole, or quinolone. Recent study in Korea has shown that modified-quadruple therapy has comparable eradication rate to concomitant therapy. However, this study did not explore the antibiotic resistance profile of Helicobacter pylori. And, there has been no comparable study of modified-quadruple therapy with bismuth-containing quadruple therapy. The aim of this study is to compare the eradication rate of modified-quadruple therapy and bismuth-containing quadruple therapy with presenting phenotypic and genotypic antibiotic resistance profile.

Interventions

  • Drug: PAMB treatment (modified quadruple therapy)
    • Randomly assign either as PAMB or PBMT group treatment
  • Drug: PBMT treatment (bismuth-containing quadruple therapy)
    • Randomly assign either as PAMB or PBMT group treatment

Arms, Groups and Cohorts

  • Experimental: PAMB group
    • PAMB treatment (modified quadruple therapy) for 14 days
  • Active Comparator: PMBT group
    • PBMT treatment (bismuth-containing quadruple therapy) for 14 days

Clinical Trial Outcome Measures

Primary Measures

  • Rate of eradication success
    • Time Frame: up to 4 weeks
    • Eradication success means negative urea breath test done at least after 4 weeks from medication administration

Secondary Measures

  • Rate of adverse events related to eradication medication
    • Time Frame: up to 4 weeks
    • Adverse events related to eradication medication
  • Rate of compliance of eradication medication administration
    • Time Frame: up to 4 weeks
    • Compliance (percentage of amount) of eradication medication administration

Participating in This Clinical Trial

Inclusion Criteria

  • Participants who had upper endoscopic examination within 3 months and diagnosed by Helicobacter pylori infection either by rapid urease test, urea breath test, or histopathologic examination. – Participants who voluntarily want to participate in this study. Exclusion Criteria:

  • Participants who had history of Helicobacter pylori eradication. – Participants who had experience of stomach resection. – Participants who had history of allergy or adverse events related to eradication medication. – Participants who had history of administration of proton-pump inhibitor within 2 weeks or Histamine 2 receptor blocker within 1 week. – Participants who had history of administration of these drugs within a week or who need continuous administration of these drugs; aspirin (except low-dose aspirin for primary prophylaxis of cardiovascular disease), intravenous or oral NSAID, anticholinergics, prostaglandin analogs, pro-motility drugs, sucralfate – Participants who had history of administration of antibiotics within 4 weeks. – Pregnant, breast feeding participant or who do not have a will to avoid pregnancy during clinical trial – Participants who are administrating one of these drugs (Lovastatin, Simvastatin, Atorvastatin, Indinavir, Ritonavir, Cyclosporin, Terfenadine, Cisapride, Pimozide, Astemizole, HIV protease inhibitors (Atazanavir, Nelfinavir), Ergotamine, Dihydroergotamine, Mizolastine, Bepridil, Ticagrelor) – Participants who have infectious mononucleosis, central nervous system infection, hematologic disease, galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, Torsades de pointes.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Chuncheon Sacred Heart Hospital
  • Collaborator
    • Hallym University Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Chang Seok Bang, Associate professor of Hallym University College of Medicine – Chuncheon Sacred Heart Hospital
  • Overall Official(s)
    • Chang Seok Bang, MD, PhD, Principal Investigator, Hallym University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.